Cara Therapeutics Company Profile (NASDAQ:CARA)

About Cara Therapeutics

Cara Therapeutics logoCara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body's peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845, and CR701. The Company's I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. The Company is developing an oral version of CR845 for the treatment of moderate-to-severe acute and chronic pain. The Company's CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with cannabinoid receptor subtypes, with no off-target activities. CR701 is in preclinical-stage of development.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CARA
  • CUSIP:
Key Metrics:
  • Previous Close: $14.55
  • 50 Day Moving Average: $13.50
  • 200 Day Moving Average: $9.34
  • 52-Week Range: $4.26 - $17.20
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.27
  • P/E Growth: 0.00
  • Market Cap: $396.95M
  • Outstanding Shares: 27,282,000
  • Beta: 3.29
Profitability:
  • Return on Equity: -50.62%
  • Return on Assets: -46.58%
Debt:
  • Current Ratio: 11.29%
  • Quick Ratio: 11.29%
Additional Links:
Companies Related to Cara Therapeutics:

Analyst Ratings

Consensus Ratings for Cara Therapeutics (NASDAQ:CARA) (?)
Ratings Breakdown: 9 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.90 (64.26% upside)

Analysts' Ratings History for Cara Therapeutics (NASDAQ:CARA)
Show:
DateFirmActionRatingPrice TargetDetails
2/22/2017HC WainwrightSet Price TargetBuy$22.00View Rating Details
11/29/2016Cantor FitzgeraldSet Price TargetBuy$24.00View Rating Details
11/24/2016ScotiabankReiterated RatingOutperform$32.00View Rating Details
11/15/2016Piper Jaffray CompaniesReiterated RatingOverweight$16.00 -> $21.00View Rating Details
11/11/2016CIBCLower Price Target$29.00 -> $28.00View Rating Details
8/7/2016Needham & Company LLCLower Price TargetBuy$27.00 -> $23.00View Rating Details
8/5/2016Stifel NicolausLower Price TargetBuy$25.00 -> $24.00View Rating Details
5/6/2016Canaccord GenuityReiterated RatingBuy$30.00View Rating Details
3/12/2016Janney Montgomery ScottReiterated RatingBuy$23.00 -> $18.00View Rating Details
2/29/2016LaidlawLower Price TargetBuy$30.00 -> $17.00View Rating Details
3/3/2015MLV & Co.Initiated CoverageBuy$26.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Cara Therapeutics (NASDAQ:CARA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
11/3/2016Q3($0.47)($0.42)$0.09 millionViewN/AView Earnings Details
8/4/2016Q216($0.42)($0.48)$0.13 million$0.08 millionViewN/AView Earnings Details
5/5/2016Q116($0.40)($0.39)$0.03 million$0.01 millionViewN/AView Earnings Details
3/10/2016Q4($0.33)($0.35)$0.53 millionViewListenView Earnings Details
11/9/2015Q315($0.27)($0.19)$1.86 million$2.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.24)($0.25)ViewListenView Earnings Details
5/12/2015Q415($0.27)($0.21)$0.70 million$0.50 millionViewListenView Earnings Details
3/26/2015Q4($0.30)($0.18)$0.91 millionViewListenView Earnings Details
11/10/2014Q314($0.22)($0.29)$0.13 million$1.13 millionViewN/AView Earnings Details
8/7/2014Q2($0.27)($0.16)$0.08 million$0.96 millionViewN/AView Earnings Details
5/12/2014Q1($0.14)($0.22)$0.30 million$0.18 millionViewN/AView Earnings Details
3/27/2014($0.18)($0.49)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cara Therapeutics (NASDAQ:CARA)
Current Year EPS Consensus Estimate: $-1.77 EPS
Next Year EPS Consensus Estimate: $-1.76 EPS

Dividends

Dividend History for Cara Therapeutics (NASDAQ:CARA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cara Therapeutics (NASDAQ:CARA)
Insider Ownership Percentage: 7.70%
Institutional Ownership Percentage: 43.29%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/20/2016Frederique Ph.D. MenzaghiVPSell6,000$9.00$54,000.00View SEC Filing  
3/17/2016Ventures Vi Lp RhoMajor ShareholderBuy400,000$4.87$1,948,000.00View SEC Filing  
2/3/2016Frederique Ph.D. MenzaghiVPSell6,000$9.04$54,240.00View SEC Filing  
1/26/2016Michael E LewisInsiderSell7,262$10.93$79,373.66View SEC Filing  
1/6/2016Derek T ChalmersCEOSell12,500$17.22$215,250.00View SEC Filing  
12/1/2015Frederique Ph.D. MenzaghiVPSell6,000$16.21$97,260.00View SEC Filing  
11/2/2015Frederique Ph.D. MenzaghiVPSell6,000$14.26$85,560.00View SEC Filing  
10/1/2015Frederique Ph.D. MenzaghiVPSell6,000$13.95$83,700.00View SEC Filing  
9/1/2015Frederique Ph.D. MenzaghiVPSell7,000$18.63$130,410.00View SEC Filing  
8/18/2015Josef SchoellCFOBuy3,000$22.10$66,300.00View SEC Filing  
6/1/2015Michael E LewisInsiderSell7,262$9.50$68,989.00View SEC Filing  
5/19/2015Dean SlagelDirectorSell188,811$10.02$1,891,886.22View SEC Filing  
4/1/2015Michael E LewisInsiderSell7,262$9.90$71,893.80View SEC Filing  
3/2/2015Michael E LewisInsiderSell7,262$10.11$73,418.82View SEC Filing  
2/2/2015Michael E LewisInsiderSell7,262$10.60$76,977.20View SEC Filing  
2/5/2014Ventures Vi Lp RhoMajor ShareholderBuy225,818$11.00$2,483,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cara Therapeutics (NASDAQ:CARA)
DateHeadline
sbwire.com logoPruritus Therapeutics Market Sizing with Competitive Landscape by 2016 - 2024 (NASDAQ:CARA)
www.sbwire.com - February 23 at 4:06 PM
News IconMedical Marijuana Market is Anticipated to Reach USD 55.8 Billion by 2025 – Market Research Report 2017 (NASDAQ:CARA)
www.abnewswire.com - February 22 at 9:16 PM
News IconFirst Week of April 21st Options Trading For Cara Therapeutics (NASDAQ:CARA)
www.stockoptionschannel.com - February 22 at 9:16 PM
News IconAnalyst Consensus Estimates & Projections are in For Shares of Cara Therapeutics, Inc. (NASDAQ:CARA) - Aiken Advocate (NASDAQ:CARA)
aikenadvocate.com - February 22 at 4:14 PM
thestreet.com logoFirst Week of April 21st Options Trading For Cara Therapeutics - TheStreet.com (NASDAQ:CARA)
www.thestreet.com - February 22 at 4:14 PM
News IconDoes Cara Therapeutics (CARA) Have More Room To Grow? - Economic Calendar (NASDAQ:CARA)
www.economiccalendar.com - February 22 at 4:14 PM
News IconProminent Runners: Cara Therapeutics Inc. (NASDAQ:CARA), Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - The Newburgh Press (NASDAQ:CARA)
newburghpress.com - February 21 at 1:42 PM
News IconHot Stocks Report Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), Cara Therapeutics, Inc. (NASDAQ:CARA) - Post Analyst (NASDAQ:CARA)
postanalyst.com - February 21 at 1:42 PM
News IconStock Price of Cara Therapeutics, Inc. (CARA) Decreases -0.61% - Highland Mirror (NASDAQ:CARA)
www.highlandmirror.com - February 21 at 1:42 PM
4-traders.com logoCara Therapeutics : Americans' Favorable Outlook on the Cannabis Market (NASDAQ:CARA)
www.4-traders.com - February 18 at 10:08 AM
News IconTechnicals in View on This Stock: Cara Therapeutics, Inc. (NASDAQ:CARA) - BVN (NASDAQ:CARA)
bvnewsjournal.com - February 17 at 6:02 PM
News IconNorth American Cannabis Stock Index Already Up 5% In 2017 (NASDAQ:CARA)
www.ino.com - February 16 at 4:12 PM
fxpips.com logoStocks Gaining on Unusual Volume, Feb. 15 – CYNO, ELOS, AYR, CUTR, SALE, TRU, OMF, HLI, SODA, TMUS, SCI, CSOD, CNA, DNB, MSCI, CSV (NASDAQ:CARA)
www.fxpips.com - February 16 at 9:00 AM
thestreet.com logoHere's What 'Superinvestors' Are Doing During the Latest Surge in the Stock Market (NASDAQ:CARA)
www.thestreet.com - February 16 at 9:00 AM
nasdaq.com logoWhy Shares of Cara Therapeutics Are Up Over 75% Since the Start of 2017 - Nasdaq (NASDAQ:CARA)
www.nasdaq.com - February 15 at 2:51 AM
News IconCara Therapeutics, Inc. (NASDAQ:CARA) Projected to Achieve EPS Of $-0.51 - Stock Observer (NASDAQ:CARA)
www.thestockobserver.com - February 14 at 2:47 AM
News IconHow High Can Cara Therapeutics Stock Go? - Fox Business (NASDAQ:CARA)
www.foxbusiness.com - February 14 at 2:47 AM
News IconStocks News Update Cliffs Natural Resources Inc (NYSE:CLF), Cara Therapeutics Inc (NASDAQ:CARA) - Financial Breaking News (NASDAQ:CARA)
wsbreakingnews.com - February 14 at 2:47 AM
fool.com logoHow High Can Cara Therapeutics Stock Go? (NASDAQ:CARA)
www.fool.com - February 13 at 4:43 PM
fool.com logoWhy Shares of Cara Therapeutics Are Up Over 75% Since the Start of 2017 (NASDAQ:CARA)
www.fool.com - February 13 at 4:43 PM
News IconHow High Can Cara Therapeutics Stock Go? - Bloomington Pantagraph (NASDAQ:CARA)
www.pantagraph.com - February 12 at 4:09 PM
News IconForward Earnings Estimate of Cara Therapeutics, Inc.(CARA) - Highland Mirror (NASDAQ:CARA)
www.highlandmirror.com - February 10 at 3:45 PM
seekingalpha.com logoCara Therapeutics; Still Potential Upside But Some Near-Term Caution Warranted - Seeking Alpha (NASDAQ:CARA)
seekingalpha.com - February 10 at 3:45 PM
fool.com logoWhy Cara Therapeutics Stock Gained 57% in January - Motley Fool (NASDAQ:CARA)
www.fool.com - February 9 at 4:26 PM
investopedia.com logoWhat Will Jeff Sessions Mean for the Marijuana Industry? (NASDAQ:CARA)
www.investopedia.com - February 9 at 4:26 PM
nasdaq.com logoWhy Cara Therapeutics Stock Gained 57% in January - Nasdaq (NASDAQ:CARA)
www.nasdaq.com - February 9 at 2:24 AM
fool.com logoWhy Cara Therapeutics Stock Gained 57% in January (NASDAQ:CARA)
www.fool.com - February 8 at 4:24 PM
News IconCara Therapeutics Inc (NASDAQ:CARA) Advances - Live Trading ... - Live Trading News (NASDAQ:CARA)
www.livetradingnews.com - February 3 at 9:24 PM
News IconLong term Growth Analysis of Cara Therapeutics, Inc. (NASDAQ:CARA) - The Newburgh Press (NASDAQ:CARA)
newburghpress.com - February 3 at 9:24 PM
News IconCara Therapeutics Inc (NASDAQ:CARA) Stock: Buy, Sell, or Hold After Massive Return? - BNL Finance (press release) (registration) (blog) (NASDAQ:CARA)
bnlfinance.com - February 3 at 9:24 PM
News IconSpending on Legal Cannabis Accelerates (NASDAQ:CARA)
www.medindia.net - February 3 at 4:22 PM
News IconSarepta Therapeutics, Inc. (NASDAQ:SRPT), Pulmatrix, Inc. (NASDAQ:PULM) (NASDAQ:CARA)
cote-ivoire.com - February 1 at 4:22 PM
News IconWhat do Analysts Say about: Sarepta Therapeutics, Incorporated (NASDAQ:SRPT) (NASDAQ:CARA)
flapship.com - February 1 at 4:22 PM
News IconCara Therapeutics Inc (CARA) Broker Price Targets For The Coming Week (NASDAQ:CARA)
xboxonezone.com - February 1 at 4:22 PM
News IconStock Jumping Abnormally High: Cara Therapeutics Inc. (NASDAQ:CARA) (NASDAQ:CARA)
hypelee.com - February 1 at 4:22 PM
News IconOverbuying Stock in Focus: Cara Therapeutics Inc (NASDAQ:CARA) (NASDAQ:CARA)
fairydetox.org - February 1 at 4:22 PM
News IconCara Therapeutics, Inc. (CARA) Receives Buy Rating from HC Wainwright (NASDAQ:CARA)
vgtoday.net - February 1 at 4:22 PM
News IconCara Therapeutics, Inc. (NASDAQ:CARA) has 1 Year Target Estimate of $22.13 (NASDAQ:CARA)
larampadinapoli.com - February 1 at 4:22 PM
finance.yahoo.com logoCara Therapeutics (CARA) Worth Watching: Stock Jumps 8% (NASDAQ:CARA)
finance.yahoo.com - February 1 at 4:22 PM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Cara Therapeutics, Inc. (NASDAQ:CARA)? - Wall Street Beacon (NASDAQ:CARA)
wsbeacon.com - January 31 at 9:36 PM
News IconStock Vacillating as Volatility Hits a High Point For Cara Therapeutics, Inc. (NASDAQ:CARA) - Wall Street Beacon (NASDAQ:CARA)
wsbeacon.com - January 31 at 9:36 PM
investing.com logo4 Stocks To Watch: CARA, TDOC, ELLI, SIG (NASDAQ:CARA)
www.investing.com - January 31 at 4:34 PM
News IconTechnical Study: Following Indicators for Cara Therapeutics Inc. (CARA) - Springdale Times (NASDAQ:CARA)
springdaletimes.com - January 30 at 9:14 PM
News IconTrading Corner: Focusing in on Shares of Cara Therapeutics, Inc. (NASDAQ:CARA) - Gilbert Daily (NASDAQ:CARA)
gilbertdaily.com - January 30 at 2:12 AM
News IconRecent Price Moves Of Shares: Cara Therapeutics Inc. (NASDAQ:CARA) (NASDAQ:CARA)
larampadinapoli.com - January 28 at 4:17 PM
newsmaker.com.au logoPruritus Therapeutics Market: Facts, Figures and Analytical Insights By 2021 (NASDAQ:CARA)
www.newsmaker.com.au - January 27 at 10:28 PM
News IconMarijuana Stocks: CARA Therapeutics Stock Is Set to Soar (NASDAQ:CARA)
www.profitconfidential.com - January 27 at 10:28 PM
News IconWorth Watching Stock: Cara Therapeutics, Inc. (NASDAQ:CARA), The Goodyear Tire & Rubber Company (NASDAQ:GT) - The Newburgh Press (NASDAQ:CARA)
newburghpress.com - January 27 at 5:27 PM
News IconStock Continues Its Ascent, Reaching New High: Cara Therapeutics, Inc. (NASDAQ:CARA) - Wall Street Beacon (NASDAQ:CARA)
wsbeacon.com - January 27 at 5:27 PM
finance.yahoo.com logoBiotech M&A Activity Expected to Rise in 2017: Latest Reports on Pulmatrix and Cara Therapeutics (NASDAQ:CARA)
finance.yahoo.com - January 27 at 5:26 PM

Social

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Where is Cara Therapeutics' stock going? Where will Cara Therapeutics' stock price be in 2017?

9 equities research analysts have issued twelve-month price objectives for Cara Therapeutics' stock. Their forecasts range from $17.00 to $32.00. On average, they anticipate Cara Therapeutics' share price to reach $23.90 in the next twelve months.

When will Cara Therapeutics announce their earnings?

Cara Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

What are analysts saying about Cara Therapeutics stock?

Here are some recent quotes from research analysts about Cara Therapeutics stock:

  • According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (1/3/2017)

  • Needham & Company LLC analysts commented, "Cara provided a quarterly corporate update yesterday. A revised IV CR845 Phase 2/3 postsurgical pain trial was initiated in Jun 2016. We believe an interim analysis may take place in 1H17, w/ final results around mid-2017. We assume a second registration trial may begin by mid-2017, w/ results available around YE17. We now estimate launch in 2019 (was 2018). We reiterate BUY, but are lowering our price target to $23 (was $27) because of launch estimate shift. In our opinion, the stock does not adequately reflect value of CR845 ($60M EV). We acknowledge hypernatremia risk in postsurgical pain, but have a favorable bias toward Phase 3 outcome." (8/7/2016)

Who owns Cara Therapeutics stock?

Cara Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Disciplined Growth Investors Inc. MN (3.26%), Chescapmanager LLC (2.51%), Franklin Resources Inc. (2.17%), Opaleye Management Inc. (1.74%), State Street Corp (1.28%) and Allianz Asset Management AG (0.95%). Company insiders that own Cara Therapeutics stock include Dean Slagel, Derek T Chalmers, Frederique PhD Menzaghi, Josef Schoell, Michael E Lewis and Ventures Vi Lp Rho.

Who sold Cara Therapeutics stock? Who is selling Cara Therapeutics stock?

Cara Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Allianz Asset Management AG, GRT Capital Partners L.L.C., Wall Street Associates and Franklin Resources Inc..

Who bought Cara Therapeutics stock? Who is buying Cara Therapeutics stock?

Cara Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Disciplined Growth Investors Inc. MN, Chescapmanager LLC, FMR LLC, Dimensional Fund Advisors LP, Russell Investments Group Ltd., Elkfork Partners LLC, State Street Corp and Flinton Capital Management LLC. Company insiders that have bought Cara Therapeutics stock in the last two years include Josef Schoell and Ventures Vi Lp Rho.

How do I buy Cara Therapeutics stock?

Shares of Cara Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cara Therapeutics stock cost?

One share of Cara Therapeutics stock can currently be purchased for approximately $14.55.

Cara Therapeutics (NASDAQ:CARA) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Cara Therapeutics (NASDAQ:CARA)

Earnings History Chart

Earnings by Quarter for Cara Therapeutics (NASDAQ:CARA)

Dividend History Chart

Dividend Payments by Quarter for Cara Therapeutics (NASDAQ:CARA)

Last Updated on 2/24/2017 by MarketBeat.com Staff